Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9555045
APP PUB NO 20110118349A1
SERIAL NO

12950033

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A composition for use in treating corneal and conjunctival lesions, includes a prostaglandin F2alpha or analogue, in a therapeutic amount, the composition being in a form suitable for topical application on the ocular surface and is free of deleterious preservative. A method for treating surface ocular conditions in a patient in need thereof, includes administering an effective amount of the composition.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • SANTEN SAS

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baudouin, Christophe Paris, FR 8 37
Daull, Philippe Soisy-sur-Seine, FR 7 13
Garrigue, Jean-Sebastien Verrieres-le-Buisson, FR 14 146
Lallemand, Frederic Fresnes, FR 23 81

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jul 31, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00